Implant-based HIV prevention methods are an emerging area of research focused on providing sustained protection against HIV through long-acting drug delivery systems. These technologies are being investigated to address challenges associated with daily medication routines and improve access to preventive care. Researchers are exploring different implant materials, drug formulations, release mechanisms, and placement methods to determine how effectively these systems can deliver preventive medicines over extended periods. Although several long-acting HIV prevention options already exist, implant technologies remain at different stages of development.
Researchers are investigating implant materials and delivery mechanisms that can protect the active medicine while allowing it to enter the bloodstream at an appropriate rate. The objective is to develop systems that provide reliable drug exposure, remain safe in body tissues, and can be removed or replaced when necessary.
Potential approaches being studied include:
Biodegradable implants: These devices are designed to break down naturally over time, potentially reducing the need for surgical removal.
Nonbiodegradable implants: These systems use durable materials to release medication gradually and may require removal when treatment ends or replacement becomes necessary.
Controlled release formulations: Specialized materials regulate how quickly a preventive medicine leaves the implant and enters the body.
Long acting antiretroviral delivery: Researchers are evaluating medicines and formulations that could maintain protective drug concentrations for extended periods.
The effectiveness of an implant depends on the medicine used, the amount released, how the body absorbs it, and whether protective concentrations remain adequate. Implant-based prevention is not a single technology, and different designs may have different benefits and limitations.
Implant-based HIV prevention research aims to expand the range of prevention choices available to people who may benefit from HIV pre-exposure prophylaxis, commonly called PrEP. Long-acting prevention approaches may help reduce the burden of frequent dosing and offer greater flexibility for people who experience difficulties maintaining regular medication routines.
However, implant technologies must undergo extensive testing before they can be considered established prevention options. Laboratory studies, preclinical investigations, and human clinical trials help researchers assess drug release, safety, tolerability, and effectiveness.
Important areas of investigation include:
Duration of protection: Researchers assess whether an implant can maintain protective medicine levels for months or longer.
Safety and tolerability: Studies examine skin reactions, inflammation, infection risks, scarring, and other potential complications at the insertion site.
Drug release consistency: Testing determines whether the device delivers a predictable amount of medicine throughout its intended lifespan.
Removal and replacement: Researchers evaluate procedures for safely removing or replacing devices when necessary.
Access and acceptability: Cost, availability, clinical infrastructure, and individual preferences may influence whether implant-based prevention is practical.
Existing long-acting HIV prevention methods, including injectable cabotegravir and injectable lenacapavir for eligible populations in approved settings, demonstrate the broader potential of sustained antiretroviral delivery. These injections are not implants, and their established uses should not be confused with investigational implant technologies.
Implant-based approaches also face challenges involving manufacturing, regulatory approval, affordability, and access to trained healthcare professionals. Further research is needed to establish which designs can provide consistent protection and acceptable safety profiles.
The development of implant-based HIV prevention may eventually broaden prevention choices, but availability depends on the specific product and its regulatory status. Current prevention decisions should be based on established, locally available options and guidance from qualified healthcare professionals.